Background: Platelet-rich plasma (PRP) has been used to augment tissue repair and regeneration after musculoskeletal injury. However, there is increasing clinical evidence that PRP does not show a consistent clinical effect.
play a detrimental role, promoting excessive inflammation, fibrosis, molecular degradation, and other undesired biological effects. In particular, Dragoo and colleagues 7, 15 found increased inflammation in leukocyte-rich PRP and thus chose leukocyte-poor PRP for selected biomedical applications.
It may be necessary to alter the current formulation of PRP to achieve a reliable clinical effect. This may be accomplished by adding factors or cells to PRP formulation to create enhanced PRP, or by subtracting a part of the growth factor milieu to create modified or indicationspecific PRP. For example, many articles provide evidence that myostatin (MSTN) and transforming growth factor b1 (TGF-b1) are particularly detrimental for muscle regeneration. § Therefore, a plausible strategy would be to remove these growth factors from the patient's PRP. As a general rule, high concentrations of certain growth factors promote myoblast proliferation and prevent differentiation, whereas depletion (or low concentrations) of these factors may induce myoblast differentiation that includes myotubule and multinucleated cell formation. 1, 27, 29, 37 This study aimed to investigate modifying autologous PRP to an indication-specific PRP by comparing the effects of the following on human skeletal muscle myoblast (HSMM) differentiation: (1) non-neutrophil containing PRP, (2) modified PRP (Mod-PRP), in which TGF-b1 and MSTN were depleted, and (3) platelet-poor plasma (PPP). Expansions of abbreviations used in this article are listed in Table 1 .
METHODS

Preparation of PRP
After institutional review board approval was obtained, 7 healthy blood donors, consisting of 4 men and 3 women with a mean age of 40 years (range, 20-60 years) provided 50 mL of blood, which was drawn by a licensed phlebotomist. A 1-mL sample of whole blood was sent to the laboratory for a complete blood count. The rest of the blood was immediately processed using the Pure PRP kit (EmCyte Corp) according to the manufacturer's instructions to create leukocyte-poor PRP and PPP fractions.
The following non-neutrophil-containing (leukocytepoor) blood plasma formulations were created: (1) PRP, (2) Mod-PRP with TGF-b1 and MSTN depletion, (3) PRP ss (PRP subjected to a second-stage spin), (4) Mod-PRP ss (Mod-PRP subjected to a second-stage spin), and (5) PPP. 
Production of Mod-PRP
MSTN and TGF-b1 were immunodepleted from PRP using 0.5 mg of antibodies per growth factor. Two types of antibodies were used against the C-terminal part of protein and against the propeptide form: anti-TGF-b1 (PAB 12738 and AF-101-NA; Abnova and R&D Systems, respectively), anti-MSTN (251651 and AF1539; Abbiotec and R&D Systems, respectively). They were coupled to protein A/G agarose beads (20421; Pierce). A Steriflip filter with 40-mm pores (SCNY00040; EMD-Millipore) was used to collect beads and elute captured growth factors and coeluting proteins with 0.2 M acetic acid. Acetic acid eluates were saved for further analysis.
PRP ss and Mod-PRP ss
After full preparation of PRP and Mod-PRP, these groups were subjected to an additional centrifugation stage for 5 minutes at 550g at room temperature. This step was added to remove platelets. Platelet removal was confirmed via hemocytometry.
HSMM Culture
HSMM cell culture (CC-2580; Lonza) was maintained according to the manufacturer's instructions. In experimental conditions, myoblasts were seeded at 10,000 cells/cm 2 in culture flasks and were treated with 2% of blood plasma formulations in myogenic DMEM/F-12 medium (Lonza) 1 day later. In the positive control group, HSMMs were treated with 2% horse serum (HS) in myogenic DMEM/F-12 medium. In the negative control group, cells were placed in 10% FBS in SkBM-2 basal media (Lonza) and seeded at 3500 cells/cm 2 to reduce spontaneous myotubule formation as a result of the high cell density and overgrowth at the end of the culture period. Plasma formulations were immediately added to HSMM culture at a 2% concentration with myogenic medium or in a dose-dependent manner (1%, 2%, 4%, and 10% final concentration). Their aliquots were frozen with protease inhibitors for further analysis. Each culture condition was performed in triplicate. Media were replaced every other day for 4 days for Western blot and RT-PCR analyses or for 6 days to observe myotubule formation. Cells were otherwise counted and viability was determined by the trypan blue exclusion method using hemocytometry. 31 
Calculation of the Fusion Index
To quantitate the proliferation effect of each plasma preparation, the average nuclei numbers per field of view were converted into the fold change in nucleated cells relative to the initial cell seeding number. The mean of the positive control group (2% HS) was set as equal to 1 for comparison (see Appendix 1, available in the online version of this article).
SDS-PAGE Analysis
Protein concentration in blood plasma formulations was measured with a 660-nm protein assay (22662; Pierce). Cell extracts were produced using CytoBuster extraction buffer (71009-3; Novagen) with protease inhibitors and benozonase-nuclease (E1014-5KU; Sigma-Aldrich). Cell extracts were spun for 10 minutes at 12,000 rpm at 4°C, and NuPAGE LDS Sample Buffer (catalog no. NP0007; Thermo Fisher Scientific) was added to the supernatants.
NuPAGE 4% to 12% SDS gels were run in nonreducing conditions for Western blot detection of TGF-b1 and MSTN because of antibody requirements. Reducing SDS-PAGE conditions were used for myosin heavy chain (MYH) analysis. SDS-PAGE reagents and molecular weight markers (LC5925) were from Invitrogen. Protein standards for Western blots (TGF-b1 [100-21; Peprotech] and MSTN [120-00; Peprotech]) were loaded at 2, 5, and 20 ng per lane. Sample loading was consistent at 25 mg/well, and controlled by gel and nitrocellulose membrane staining.
Western Blot Analysis
Proteins from gels were transferred onto nitrocellulose membrane. Wet transfer conditions for miniblots were optimized in our laboratory for TGF-b1 and MSTN as follows: NuPAGE transfer buffer (NP0006; Invitrogen) without methanol, 30-V constant voltage, for 30 minutes at room temperature. Membranes were blocked using Super-Block T20 (PI37535; Pierce) and incubated with primary antibodies from 6 hours up to overnight, at room temperature. Primary antibodies (from R&D Systems) were as follows: anti-TGF-b1 AF-246-NA and MAB240, anti-MSTN antibodies AF788 and MAB788, and MYH antibody MAB4470. GAPDH antibodies (MA5-15738; Pierce) were used for protein loading control. Secondary horseradish peroxidase-labeled antibodies were from Jackson Immuno Research Laboratories. Enhanced chemiluminescence detection was performed with SuperSignal West Dura Substrate (34075; Pierce). Western blot images were scanned and digitized using ImageJ software (version 1.49; National Institutes of Health). Densitometry analysis was used to generate semiquantitative data from the Western blot images.
Reverse Transcription and qPCR Analysis
The expression levels of target genes were determined by qPCR with specific TaqMan primers for MYH2, Hs00430 042_m1, myogenin (MyoG), Hs01072232_m1, myogenesis enhancer factor 2C (MEF2C), Hs00231149_m1, MSTN, and Hs00976237_m1, with 18S RNA, Hs99999901_s1 (Life Technologies) as the internal reference (for the reverse transcription and qPCR analysis protocol, see Appendix 2, available online).
Immunofluorescence Staining
HSMM cells were seeded on Thermanox coverslips (Thermo Fisher Scientific) and cells were treated accordingly for 6 days and then washed 3 times with PBS before being fixed in 4% paraformaldehyde for 15 minutes at room temperature. Next, cells were incubated with PBT1 (PBS/1% bovine serum albumin/5% normal goat serum/0.1% Triton X-100) for 60 minutes at room temperature and then with monoclonal anti-myosin (skeletal, fast) antibody (MY-32; Sigma-Aldrich) at a 1:50 dilution in PBT1, overnight at 4°C, followed by 2 washes with PBT1 and 2 washes with PBT2 (PBS/0.1% bovine serum albumin/0.1% Triton X-100). Next, cells were incubated with Alexa Fluor 546-conjugated goat anti-mouse (Thermo Fisher Scientific) at 1:250 for 2 hours at room temperature. Finally, cells were washed twice in PBT2, followed by 3 washes with PBS, and the coverslips were mounted on glass slides with VectaShield antifade mounting medium with DAPI (Vector Laboratories). Images were acquired using an Axio Observer Z1 fluorescent microscope, with Zen Pro software (Carl Zeiss Inc).
Statistical Analysis
Statistical analysis was conducted using SAS software (version 9.4; SAS Institute Inc), and data were presented as the mean 6 standard deviation. First, the normality and homogeneity of data distribution were determined by the Shapiro-Wilk and Levene tests, respectively. Normality testing indicated nonparametric data, so the Kruskal-Wallis test was used. The Wilcoxon 2-sample test was used for post hoc analysis for multiple comparisons, followed by step-down Bonferroni test for P value adjustment. All reported P values were 2 tailed and were determined to be significant at .05.
RESULTS
PRP Preparation
There was considerable individual variation between blood donors with regard to platelet and WBC concentration at baseline and after PRP preparation. Platelet enrichment in PRP varied from 2 to 5 times (mean 3.71 6 1.26) compared with blood plasma values ( Table 2 ).
Effects of PRP and PPP on Myoblast Differentiation
HSMMs grown in basal media with 10% FBS (negative control) exhibited no MYH staining upon viewing with confocal microscopy, whereas cells treated with myogenic DMEM/ F-12 medium and 2% HS (positive control) exhibited high levels of MYH staining and formed well-organized polynucleated myotubes (Figure 1 ). The fusion index results in Figure 2 reflected these observations: there was a significant increase in the positive control (9.22 6 2.11) compared with the negative control (0.08 6 0.07; P = .001). The addition of PRP to cultures had no significant effect on myoblast differentiation or cell fusion (0.15 6 0.11). However, PPP (17.61 6 1.81) induced a significant increase of cell differentiation and myotubule formation compared with the PRP (P = .002), Mod-PRP (0.08 6 0.09; P = .002), and negative control groups (P = .002).
Western blot analysis of myoblast cell extracts showed no production of MYH in the PRP groups but increased MYH production in the PPP and PRP ss groups (Figure 3 ).
The RT-PCR analysis showed no significant fold increase in MYH mRNA in the PRP group (1.06 6 0.65) compared with the negative control (1.00 6 0.10; P .99) ( Figure 4 ). However, there was significantly less MYH mRNA in the PRP group compared with the positive control (6.82 6 0.97; P = .01). The PPP group displayed a significant fold increase in MYH mRNA (12.38 6 5.81) compared with PRP (P = .03) and the negative control (P = .02), but there was no difference compared with the positive control (P = .05). There were no significant changes in MSTN mRNA levels in the PRP or PPP groups compared with each other, or any other group, except for the negative control.
MyoG expression is induced when myoblasts commit to terminal differentiation through myogenesis. As the transcriptional activator of MyoG, the expression and binding of MEF2C to its promoter region promotes the transition of myoblasts from proliferation toward differentiation. 17 RT-PCR analysis showed that MyoG expression levels in the PRP group (2.27 6 0.94) were significantly lower than the positive control (10.73 6 5.82; P = .014). Although the difference between the PRP group and the negative 
Immunodepletion of TGF-b1 and MSTN to Create Mod-PRP
Western blot analysis illustrated a decrease in TGF-b1 and MSTN concentrations in Mod-PRP compared with standard PRP preparation ( Figure 5, A and B) . MYH immunostaining of the 2% Mod-PRP group showed only minimal effects of myoblast differentiation and myotubule formation compared with the standard PRP formulation or the negative control group (Figure 1 ), but it exhibited higher production of MYH than the standard PRP formulation on Western blot analysis of HSMM cell extracts ( Figure 5C ). The fusion index study ( Figure 2 ) showed a similar result as in the MYH2 immunostaining. There was no difference in Mod-PRP group (0.08 6 0.09) compared with the negative control (0.08 6 0.07; P .99) or the standard PRP group (0.05 6 0.11; P = .87).
The RT-PCR analysis showed no significant fold increase in MYH mRNA in the Mod-PRP group (1.10 6 0.82) compared with standard PRP (1.06 6 0.65) or the negative control (1.00; P .99) ( Figure 4 ). There was significantly less MSTN RNA in the Mod-PRP group (0.46 6 0.09) compared with the negative control (1.00 6 0.11; P = .0114), but there was no significant difference compared with standard PRP (0.50 6 0.29; P .99) or the positive control (2% HS; 0.40 6 0.18; P .99). The MyoG mRNA levels were not significantly different between the Mod-PRP group (1.96 6 1.11) and the negative control (1.00 6 0.18; P = .381) or the standard PRP group (2.27 6 0.94; P = .995). The expression of MEF2C showed similar results, with no difference between the Mod-PRP group (0.85 6 0.46) and the negative control (1.00 6 0.14) or the standard PRP group (0.99 6 0.21; P = .983).
The Effects of a Secondary Spin: PRP ss and Mod-PRP ss
Subjecting the PRP and Mod-PRP to a second-stage spin led to complete removal of all countable platelets in the PRP ss and Mod-PRP ss groups, which was confirmed via hemocytometry (data not shown).
MYH immunostaining illustrated a marked increase in myoblast differentiation and myotubule formation in the PRP ss and Mod-PRP ss groups compared with standard PRP and Mod-PRP groups, respectively (Figure 1 ). Corresponding to these results, the fusion index study in Figure  2 indicated that the PRP ss group (14.11 6 1.56) had a significant increase in myoblast fusion compared with the standard PRP group (0.15 6 0.11; P \ .001) or the Mod-PRP group (0.08 6 0.09; P \ .0001). In addition, the Mod-PRP ss group (7.60 6 2.96) revealed a marked increase of cell fusion relative to the standard PRP group (P = .013) and the Mod-PRP group (P = .013). MYH was also seen in the cell extracts of myoblasts in the PRP ss groups in increased concentration compared with the PRP groups ( Figure 5D ).
RT-PCR showed a significant increase in the MYH mRNA fold change in the PRP ss group (9.68 6 6.18) compared with the standard PRP formulation (1.06 6 0.65; P = .0120) and the negative control (1.00 6 0.10; P = .0120). The PRP ss group had MYH mRNA levels comparable with the positive control group (6.82 6 0.97; P .99) or the PPP group (12.38 6 5.81; P .99). The qPCR analysis showed a significant increase in MyoG expression in the PRP ss group (8.01 6 1.75) compared with the negative control (1.00 6 0.18; P = .002) or the standard PRP group (2.27 6 0.94; P = .002). MEF2C expression was significantly increased in the PRP ss group (2.95 6 0.68) relative to the negative control (1.00 6 0.14; P = .007) or the standard PRP group (0.99 6 0.21; P = .006) ( Figure 4 ).
Mod-PRP ss displayed a significant increase in MYH mRNA fold change (7.00 6 3.69) compared with Mod-PRP groups (1.10 6 0.82; P = .0126) but was comparable with the positive control group (6.82 6 0.97; P .99) or the PPP group (12.38 6 5.81; P .99) ( Figure 4 ). There was also no significant change in MSTN RNA in the PRP ss or Mod-PRP ss groups compared with any other group except the negative control. MyoG expression in the Mod-PRP ss group (8.32 6 2.97) was significantly increased compared with the negative control (1.00 6 0.18; P = .006) or the Mod-PRP group (1.96 6 1.11; P = 0.009) ( Figure 4C) . Similarly, there were significant increases in MEF2C expression between the Mod-PRP ss group (2.60 6 0.74) and the negative control (1.00 6 0.14; P = .011) and Mod-PRP groups (0.85 6 0.46; P = 0.004). However, there were no significant difference in both MyoG and MEF2C expression among the positive control, PRP ss , Mod-PRP ss , and PPP groups ( Figure 4D ).
Dose-dependent Effect of PPP
Western blot densitometry analysis showed an increase of MYH expression with increasing PPP concentration changing from 1% to 4% (Figure 3) ; however, the effect was diminished at 10% PPP.
Effect of Plasma Preparations on Skeletal Muscle Myoblast Proliferation
Although a comprehensive analysis of myoblast proliferation is outside the scope of this article, an evaluation of growth kinetics was performed to identify whether proliferative changes were occurring in groups that were not induced into the differentiation phenotype. The results illustrated in Figure 6 showed that the fold change in nucleated myoblasts was highest in the negative control group (4.40 6 0.29), which was significantly higher than all other treatment groups (P \ .0001). The standard PRP group (1.39 6 0.12) exhibited a significant increase in cell numbers compared with the positive control (1.00 6 0.17; P = .013), the PRP ss group (0.73 6 0.03; P = .0001), and the PPP group (0.79 6 0.09; P = .0003). Similarly, the Mod-PRP group (1.32 6 0.14) showed a higher number of nucleated cells relative to the positive control (P = .048), the PRP ss group (P = .0007), and the PPP group (P = .001). The Mod-PRP ss group (1.11 6 0.28) was not significantly lower in cell number compared with the standard PRP group and the Mod-PRP, owing to its higher variation range. In conclusion, the lowest cell proliferation was observed in the PRP ss and PPP groups, which were the groups that also displayed the largest induction into the differentiation phenotype (Figures 2-5 ).
DISCUSSION
PRP therapy has been scrutinized recently because of its lack of consistent effectiveness in treating a variety of orthopaedic disorders. This lack of efficacy may be attributable in part to the large amount of growth factors present, some of which promote cell proliferation while others promote cell differentiation. Altering the current formulation of PRP is one strategy that could be employed to improve efficacy. This may be accomplished by either adding factors or cells to the PRP formulation to create enhanced PRP or by subtracting a part of the growth factor milieu to create modified or indication-specific PRP. This article evaluates the use of modified PRP to augment myoblast differentiation into muscle tissue.
In general, myoblasts may be induced into 2 main pathways: the proliferation path that leads to an increase in the number of cells, thought to be necessary initially at the site of injury, or the differentiation path that leads to induction of the cells into muscle tissue. 1, 27, 32, 37, 39, 42, 46 Biologics that aim to improve the body's muscle regeneration capacity must contain a precise growth factor milieu to induce myoblasts down the differentiation path. For example, standard PRP formulations contain MSTN and TGF-b1, and there is ample evidence that these factors are detrimental for muscle regeneration. jj It is therefore plausible that jj References 4, 9, 11, 14, 18, 23, 24, [28] [29] [30] 34, 35, 40, [42] [43] [44] 47. removing these 2 factors (Mod-PRP) from PRP may improve its myoblast differentiation efficiency.
Our data illustrate that unmodified PRP does not promote myogenic differentiation or formation of multinucleated myotubes but may promote myoblast proliferation. Li et al 26 also previously described PRP's influence on myoblast proliferation. By contrast, PPP and PRP formulations subjected to a secondary centrifugal spin (PRP ss and Mod-PRP ss ) showed a robust ability to induce human myoblasts into the differentiation state, creating multinucleated myotubules (Figure 1 ). Our fusion index results for the positive control (2% HS) in Figure 2 are lower than the numbers reported in the literature, 20, 38 which we believe is attributable to the use of a lower cell density in our study that minimizes MYH2 expression from spontaneous fusion. However, our data clearly demonstrate the significant difference among different treatment groups that support the observations of myotube formation in Figures 1, 2, and 4 . Together, these data may have marked translational significance and may be used to design animal and human trials to establish clinical efficacy.
Although our protocol was successful in engineering Mod-PRP, with depletion of TGF-b1 and MSTN, its effect on myoblast differentiation was minimal, evidenced by an increase in MYH production only in Western blotting ( Figure 5C ) but not with immunostaining or RT-PCR analysis. There are many plausible reasons for the failure of Mod-PRP to fully induce cell differentiation. First, it was not possible to entirely deplete TGF-b1 and MSTN from the PRP, because these growth factors were continually released by platelets and from multiple high molecular weight complexes (growth factor ''depots'') during the culture period. 2, 3, 22, 25, 33 However, the immunodepletion was improved when the time of PRP incubation was increased to 1.5 hours and the antibody concentration was increased to 250 mg/mL of PRP. Second, the minimal required concentration of antibodies may vary depending on the growth factor concentration in the donor's plasma, as well as the protocol used for PRP preparation (platelet count, etc). Third, TGF-b1 and MSTN may not be the only critical growth factors inhibiting induction into the differentiation phenotype.
PRP ss and Mod-PRP ss formulations appeared to induce the myoblasts into the differentiated state. Analysis confirmed that the second spin removed all platelets from these formulations, whereas other growth factors, including platelet-derived growth factor (PDGF) and other protein complexes, may have also been removed. Further analysis will be required to identify the additional growth factors removed via the second spin technique.
PPP, long regarded as the waste product of PRP preparation, exhibited the most promise as an inexpensive, clinically translatable treatment. Although by its definition PPP does not contain a significant number of platelets, it is still a source of growth factors. Previous studies indicate that PPP may contain decreased concentrations of PDGF as well as other bioactive factors, which may be responsible for its effect on myoblasts. 8, 10, 12, 16, 21, 45 Our data also indicated that there is some dose dependence when using PPP for myoblast differentiation, with the ideal range likely between 2% and 4% (Figure 3 ).
There are a few shortcomings with our approach. Although our second spin (PRP ss and Mod-PRP ss ) and PPP groups clearly induced myoblast differentiation, the exact growth factors that were removed from the formulations are unknown. Individual growth factor analysis of the formulations is a massive undertaking and will be the subject of a future proteomic investigation. Second, although the formulations showing the most myoblast proliferation (PRP, Mod-PRP, and negative control) were inversely correlated with the formulations (PPP, PRP ss , Mod-PRP ss , and positive control) that led to myoblast differentiation ( Figure 6 ), a thorough analysis of the proliferation pathway was not performed because it was not the premise of this investigation.
In summary, PPP and leukocyte-poor PRP preparations subjected to a second spin to remove the platelets led to induction of myoblast cells into the muscle differentiation pathway, whereas unmodified PRP may lead to myoblast proliferation. Further studies investigating the individual growth factors that were removed from the PPP, PRP ss , and Mod-PRP ss groups, as well as translational clinical trials, will elucidate the efficacy of this approach for muscle regeneration therapy.
